UK pharma giant AstraZeneca has submitted an application to the Japanese authorities for the use of a new lung cancer drug.
The company has sent a request to Japan's Pharmaceuticals and Medical Devices Agency for Tagrisso to be used as a first-line drug for patients treatment of patients with specific types of inoperable or recurrent non-small cell lung cancer.
The Japanese submission is based on data from the Phase III FLAURA trial, in which Tagrisso significantly improved progression-free survival compared with current first-line drugs in previously-untreated patients with locally-advanced or metastatic cancers.
AstraZeneca shares rose to 5030p at one point in late morning trading from an opening of 4981p before slipping back to hover around the 5000p mark.
US approves asthma drug
The news comes just a fortnight after the US Food & Drug Administration approved the use of AstraZeneca's new drug Fasenra for severe cases of asthma.
AstraZeneca CEO Pascal Soriot said: “This is the first approval from our respiratory biologics portfolio and the latest in a series of significant milestones for our company as we deliver on our pipeline-driven transformation.”
AstraZeneca is also looking to boost its Chinese business through a new drug development joint venture with a state-backed private equity fund.